> top > docs > PubMed:27384305 > annotations

PubMed:27384305 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-134 Sentence denotes Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
T2 135-355 Sentence denotes Nonalcoholic fatty liver disease (NAFLD) defines a spectrum of conditions from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis and is regarded as the hepatic manifestation of the metabolic syndrome.
T3 356-508 Sentence denotes Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis.
T4 509-628 Sentence denotes Glucocorticoids can be reactivated in liver through 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme activity.
T5 629-706 Sentence denotes Inhibition of 11β-HSD1 has been suggested as a potential treatment for NAFLD.
T6 707-979 Sentence denotes To test this, male mice with global (11β-HSD1 knockout [KO]) and liver-specific (LKO) 11β-HSD1 loss of function were fed the American Lifestyle Induced Obesity Syndrome (ALIOS) diet, known to recapitulate the spectrum of NAFLD, and metabolic and liver phenotypes assessed.
T7 980-1152 Sentence denotes Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11β-HSD1KO and LKO mice were not protected from systemic metabolic disease.
T8 1153-1342 Sentence denotes Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11β-HSD1KO, LKO, and control mice.
T9 1343-1530 Sentence denotes Unexpectedly, histological analysis revealed significantly increased levels of immune foci present in livers of 11β-HSD1KO but not LKO or control mice, suggestive of a transition to NASH.
T10 1531-1624 Sentence denotes This was endorsed by elevated hepatic expression of key immune cell and inflammatory markers.
T11 1625-1771 Sentence denotes These data indicate that 11β-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet.
T12 1772-1936 Sentence denotes However, global deficiency of 11β-HSD1 did increase markers of hepatic inflammation and suggests a critical role for 11β-HSD1 in restraining the transition to NASH.
T1 0-134 Sentence denotes Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.
T2 135-355 Sentence denotes Nonalcoholic fatty liver disease (NAFLD) defines a spectrum of conditions from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis and is regarded as the hepatic manifestation of the metabolic syndrome.
T3 356-508 Sentence denotes Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis.
T4 509-628 Sentence denotes Glucocorticoids can be reactivated in liver through 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme activity.
T5 629-706 Sentence denotes Inhibition of 11β-HSD1 has been suggested as a potential treatment for NAFLD.
T6 707-979 Sentence denotes To test this, male mice with global (11β-HSD1 knockout [KO]) and liver-specific (LKO) 11β-HSD1 loss of function were fed the American Lifestyle Induced Obesity Syndrome (ALIOS) diet, known to recapitulate the spectrum of NAFLD, and metabolic and liver phenotypes assessed.
T7 980-1152 Sentence denotes Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11β-HSD1KO and LKO mice were not protected from systemic metabolic disease.
T8 1153-1342 Sentence denotes Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11β-HSD1KO, LKO, and control mice.
T9 1343-1530 Sentence denotes Unexpectedly, histological analysis revealed significantly increased levels of immune foci present in livers of 11β-HSD1KO but not LKO or control mice, suggestive of a transition to NASH.
T10 1531-1624 Sentence denotes This was endorsed by elevated hepatic expression of key immune cell and inflammatory markers.
T11 1625-1771 Sentence denotes These data indicate that 11β-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet.
T12 1772-1936 Sentence denotes However, global deficiency of 11β-HSD1 did increase markers of hepatic inflammation and suggests a critical role for 11β-HSD1 in restraining the transition to NASH.

TEST-DiseaseOrPhenotypicFeature

Id Subject Object Predicate Lexical cue #label
T1 79-97 DiseaseOrPhenotypicFeature denotes Metabolic Syndrome D024821
T2 101-133 DiseaseOrPhenotypicFeature denotes Nonalcoholic Fatty Liver Disease D065626
T3 135-167 DiseaseOrPhenotypicFeature denotes Nonalcoholic fatty liver disease D065626
T4 169-174 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T5 221-230 DiseaseOrPhenotypicFeature denotes steatosis DISEASE
T6 234-262 DiseaseOrPhenotypicFeature denotes nonalcoholic steatohepatitis D065626
T7 264-268 DiseaseOrPhenotypicFeature denotes NASH D065626
T8 274-283 DiseaseOrPhenotypicFeature denotes cirrhosis D005355
T9 336-354 DiseaseOrPhenotypicFeature denotes metabolic syndrome D024821
T10 384-393 DiseaseOrPhenotypicFeature denotes steatosis DISEASE
T11 700-705 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T12 859-866 DiseaseOrPhenotypicFeature denotes Obesity D009765
T13 928-933 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T14 1134-1151 DiseaseOrPhenotypicFeature denotes metabolic disease D008659
T15 1220-1225 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T16 1277-1286 DiseaseOrPhenotypicFeature denotes steatosis DISEASE
T17 1525-1529 DiseaseOrPhenotypicFeature denotes NASH D065626
T18 1697-1714 DiseaseOrPhenotypicFeature denotes metabolic disease D008659
T19 1751-1756 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T20 1843-1855 DiseaseOrPhenotypicFeature denotes inflammation D007249
T21 1931-1935 DiseaseOrPhenotypicFeature denotes NASH D065626

TEST-ChemicalEntity

Id Subject Object Predicate Lexical cue ID:
T1 47-55 ChemicalEntity denotes Fructose http://purl.obolibrary.org/obo/CHEBI_28757
T2 356-371 ChemicalEntity denotes Glucocorticoids http://purl.obolibrary.org/obo/CHEBI_24261
T3 442-457 ChemicalEntity denotes free fatty acid D005230
T4 509-524 ChemicalEntity denotes Glucocorticoids http://purl.obolibrary.org/obo/CHEBI_24261
T5 565-593 ChemicalEntity denotes hydroxysteroid dehydrogenase D006913
T6 1045-1052 ChemicalEntity denotes glucose D005947|http://purl.obolibrary.org/obo/CHEBI_4167|http://purl.obolibrary.org/obo/CHEBI_17234
T9 1186-1198 ChemicalEntity denotes triglyceride D014280|http://purl.obolibrary.org/obo/CHEBI_17855

TEST-OrganismTaxon

Id Subject Object Predicate Lexical cue
T1 23-27 OrganismTaxon denotes Mice
T2 726-730 OrganismTaxon denotes mice
T3 1096-1100 OrganismTaxon denotes mice
T4 1337-1341 OrganismTaxon denotes mice
T5 1489-1493 OrganismTaxon denotes mice
T6 1669-1673 OrganismTaxon denotes mice

Test-GeneOrGeneProduct

Id Subject Object Predicate Lexical cue
T1 9-13 GeneOrGeneProduct denotes HSD1
T2 79-97 GeneOrGeneProduct denotes Metabolic Syndrome
T3 336-354 GeneOrGeneProduct denotes metabolic syndrome
T4 565-593 GeneOrGeneProduct denotes hydroxysteroid dehydrogenase
T5 606-610 GeneOrGeneProduct denotes HSD1
T6 647-651 GeneOrGeneProduct denotes HSD1
T7 748-752 GeneOrGeneProduct denotes HSD1
T8 797-801 GeneOrGeneProduct denotes HSD1
T9 1654-1658 GeneOrGeneProduct denotes HSD1
T10 1806-1810 GeneOrGeneProduct denotes HSD1
T11 1893-1897 GeneOrGeneProduct denotes HSD1

Test-merged-2

Id Subject Object Predicate Lexical cue #label ID:
T50934 47-55 ChemicalEntity denotes Fructose http://purl.obolibrary.org/obo/CHEBI_28757
T64669 356-371 ChemicalEntity denotes Glucocorticoids http://purl.obolibrary.org/obo/CHEBI_24261
T65869 442-457 ChemicalEntity denotes free fatty acid D005230
T86508 509-524 ChemicalEntity denotes Glucocorticoids http://purl.obolibrary.org/obo/CHEBI_24261
T82185 565-593 ChemicalEntity denotes hydroxysteroid dehydrogenase D006913
T52739 1045-1052 ChemicalEntity denotes glucose D005947|http://purl.obolibrary.org/obo/CHEBI_4167|http://purl.obolibrary.org/obo/CHEBI_17234
T70074 1186-1198 ChemicalEntity denotes triglyceride D014280|http://purl.obolibrary.org/obo/CHEBI_17855
T2835 9-13 GeneOrGeneProduct denotes HSD1
T55706 79-97 GeneOrGeneProduct denotes Metabolic Syndrome
T44636 336-354 GeneOrGeneProduct denotes metabolic syndrome
T8199 565-593 GeneOrGeneProduct denotes hydroxysteroid dehydrogenase
T34868 606-610 GeneOrGeneProduct denotes HSD1
T66530 647-651 GeneOrGeneProduct denotes HSD1
T96899 748-752 GeneOrGeneProduct denotes HSD1
T29658 797-801 GeneOrGeneProduct denotes HSD1
T50567 1654-1658 GeneOrGeneProduct denotes HSD1
T90435 1806-1810 GeneOrGeneProduct denotes HSD1
T49845 1893-1897 GeneOrGeneProduct denotes HSD1
T2951 23-27 OrganismTaxon denotes Mice
T14729 726-730 OrganismTaxon denotes mice
T71421 1096-1100 OrganismTaxon denotes mice
T50399 1337-1341 OrganismTaxon denotes mice
T65830 1489-1493 OrganismTaxon denotes mice
T97901 1669-1673 OrganismTaxon denotes mice
T1 79-97 DiseaseOrPhenotypicFeature denotes Metabolic Syndrome D024821
T2 101-133 DiseaseOrPhenotypicFeature denotes Nonalcoholic Fatty Liver Disease D065626
T3 135-167 DiseaseOrPhenotypicFeature denotes Nonalcoholic fatty liver disease D065626
T4 169-174 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T5 221-230 DiseaseOrPhenotypicFeature denotes steatosis DISEASE
T6 234-262 DiseaseOrPhenotypicFeature denotes nonalcoholic steatohepatitis D065626
T7 264-268 DiseaseOrPhenotypicFeature denotes NASH D065626
T8 274-283 DiseaseOrPhenotypicFeature denotes cirrhosis D005355
T9 336-354 DiseaseOrPhenotypicFeature denotes metabolic syndrome D024821
T10 384-393 DiseaseOrPhenotypicFeature denotes steatosis DISEASE
T11 700-705 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T12 859-866 DiseaseOrPhenotypicFeature denotes Obesity D009765
T13 928-933 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T14 1134-1151 DiseaseOrPhenotypicFeature denotes metabolic disease D008659
T15 1220-1225 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T16 1277-1286 DiseaseOrPhenotypicFeature denotes steatosis DISEASE
T17 1525-1529 DiseaseOrPhenotypicFeature denotes NASH D065626
T18 1697-1714 DiseaseOrPhenotypicFeature denotes metabolic disease D008659
T19 1751-1756 DiseaseOrPhenotypicFeature denotes NAFLD D065626
T20 1843-1855 DiseaseOrPhenotypicFeature denotes inflammation D007249
T21 1931-1935 DiseaseOrPhenotypicFeature denotes NASH D065626